Mumbai, June 02, 2020: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Vivlodex® Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at Lupin’s Aurangabad facility, India, and is expected to be launched shortly.
Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex®) had an annual sales of approximately USD 14 million in the U.S. (IQVIA MAT March 2020).
Corporate Comm India (CCI Newswire)
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…